drugset / Trial / NCT02052388

Efficacy and Safety Study of Brilacidin to Treat Serious Skin Infections

NCT02052388

Phase 2 Completed 215 enrolled Cellceutix Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the safety and efficacy of three different dosing regimens of brilacidin compared to daptomycin for the treatment of serious skin infections. This study will aid in selecting the appropriate dose of brilacidin for later stage studies.

Timeline

Start
2014-02
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Brilacidin Other / unclassified 0.3 mg/kg Intravenous
Subject Brilacidin Other / unclassified 0.6 mg/kg Intravenous
Subject Brilacidin Other / unclassified 0.8 mg/kg Intravenous
Comparator Daptomycin Other / unclassified 4 mg/kg Intravenous